^
23h
Trial initiation date
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation
|
abiraterone acetate • prednisone • saruparib (AZD5305)
8d
Extracellular vesicles derived from TNF-α-preconditioned mesenchymal stem cells mitigate inflammatory retinal injury. (PubMed, Extracell Vesicles Circ Nucl Acids)
In vivo, T-sEV treatment significantly preserved retinal a- and b-wave amplitudes and structural integrity... TNF-α preconditioning enhances MSC-derived sEV therapeutic capacity by enriching their anti-inflammatory miRNAs. T-sEV suppress pro-inflammatory macrophage activation and provide superior neuroprotection in a retinal degeneration model, indicating a safe and promising cell-free therapeutic strategy.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ITGAM (Integrin, alpha M) • IL1R1 (Interleukin 1 receptor, type I) • CD86 (CD86 Molecule)
|
Akeega (abiraterone/niraparib)
8d
Synergistic piezo-immunotherapy enabled by lithium-doped SrTiO3 nanocatalysts for potent tumor ablation through ROS generation and immune activation. (PubMed, Regen Biomater)
As quantified by PFM, its surface potential and piezoelectric (butterfly-type) amplitude were ∼2.23-fold higher than those of the unmodified sample...The integration of piezocatalysis with immune activation resulted in a multimodal synergistic therapy that substantially improved overall antitumor efficacy. This work provides an innovative material-based strategy for enhancing tumor treatment through functional modulation and synergistic mechanisms.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Akeega (abiraterone/niraparib)
8d
SNV1521-101: SNV1521 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=400, Recruiting, Synnovation Therapeutics, Inc. | N=200 --> 400 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
Enrollment change • Trial completion date • Trial primary completion date
|
abiraterone acetate • Nubeqa (darolutamide)
13d
Preservation of Human Colonic Stem Cells Requires an ERK Dynamics Checkpoint Mediated by AKT. (PubMed, bioRxiv)
Stem cells must balance self-renewal and differentiation while remaining responsive to continuous mitogenic stimulation to preserve tissue homeostasis. When self-renewal is impaired, wound healing and barrier integrity decline, whereas loss of proper differentiation drives tumorigenesis. Our findings demonstrate that this balance in the human colon is achieved through temporal control of kinase signaling rather than modulation of ligand availability. By establishing an AKT-dependent ERK dynamics checkpoint, colonic stem cells suppress differentiation-inducing ERK pulses while maintaining growth factor responsiveness. These results identify kinase dynamics as a fundamental determinant of epithelial homeostasis and suggest that subtle alterations in these dynamics may destabilize tissue organization during regeneration or chronic inflammation. Temporal encoding of kinase activity thus represents a central organizing principle in human stem cell biology.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Akeega (abiraterone/niraparib)
14d
Repeated Latency Prolongation of the Orbicularis Oris Muscle During Intraoperative Transcranial Facial Motor Evoked Potential Monitoring: A Case Report. (PubMed, Cureus)
In this rare case, we demonstrate reproducible Tc-fMEP latency prolongation suggestive of impaired neural conduction during vestibular schwannoma surgery. Latency prolongation of facial nerve motor evoked potentials, together with amplitude reduction, may represent a potential indicator of facial nerve functional impairment.
Journal
|
NF2 (Neurofibromin 2)
|
Akeega (abiraterone/niraparib)
15d
Quaternary Ammonium Compound Induced Electrocardiogram Abnormalities with Body Fat as a Potential Effect Modifier: A Longitudinal Multiomics Panel Study in Elderly Adults. (PubMed, Environ Sci Technol)
Specifically, both BTMAC and DAD were associated with prolonged QRS time, whereas C8-DDAC was related to increased QT interval, QTc interval, and RV5/SV1 amplitude, as well as a reduced QRS time...Taken together, this study provides the first population-based evidence of QAC-associated cardiotoxicity and proposes the underlying biomolecular alternations. These insights offer a scientific foundation for developing targeted strategies to prevent and mitigate environmentally induced cardiovascular risks in susceptible populations.
Journal
|
NAP1L1 (Nucleosome Assembly Protein 1 Like 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
Akeega (abiraterone/niraparib)
17d
Enrollment closed
|
Nubeqa (darolutamide) • saruparib (AZD5305)
22d
Endoplasmic reticulum stress-based ATF6 signaling pathway: evaluation of 4-PBA improving retinal state in myopic guinea pigs. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Retinas in the LIM group showed thinning, disorganized layers, and reduced FERG amplitudes (Cone-b/Rod-b/OPs)...4-PBA mitigates retinal damage in myopia by inhibiting ATF6-mediated ERS, reducing calcium overload, restoring mitochondrial function, and suppressing the ATF6-CHOP-Bax apoptotic cascade. This study identifies the ATF6 pathway as a therapeutic target for myopic retinopathy and supports 4-PBA's potential as a retinal protective agent.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ATF6 (Activating Transcription Factor 6) • ANXA5 (Annexin A5)
|
Akeega (abiraterone/niraparib)
22d
Clinical Characteristics and Development of a Risk-Identification Model for Incidentally Detected Cancer in Patients with Diabetes: A Case-Control Study. (PubMed, Diabetes Metab Syndr Obes)
Model A predictors were age, sex, body mass index, HbA1c, mean glucose, mean amplitude of glycaemic excursions (MAGE) from the first 72 h of capillary glucose, 2-hour C-peptide, apolipoprotein A-I (ApoA-I), albumin, and sodium-glucose cotransporter 2 (SGLT2) inhibitor use...Adding tumour markers, particularly CYFRA21-1, improved discrimination. Prospective multicentre validation and assessment of clinical and economic impact are warranted before implementation.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • KRT19 (Keratin 19) • APOA1 (Apolipoprotein A-I) • CA 19-9 (Cancer antigen 19-9)
|
Akeega (abiraterone/niraparib)
27d
APOE4 and doxorubicin impair inhibitory interneuron function and homeostatic regulation in the entorhinal cortex. (PubMed, PLoS One)
For EC pyramidal neurons, the chemotherapeutic agent doxorubicin caused increases in the amplitudes of both spontaneous excitatory and inhibitory post-synaptic currents, with significant responses (***p < 0.001; **p < 0.01 respectively) in APOE3 brains. Doxorubicin doubled the percentage of PV cells that showed inactivation block in APOE3 brains (25% to 52%) but had no effect on APOE4 brains (50% to 54%). This ex vivo study suggests that APOE4 impairs homeostatic synaptic transmission in pyramidal cells under control conditions and causes a lack of responsiveness to a stressor (doxorubicin treatment) in PV cells.
Journal
|
APOE (Apolipoprotein E)
|
doxorubicin hydrochloride • Akeega (abiraterone/niraparib)
29d
A review of the circadian regulation of stem cells: harnessing the internal body clock for enhanced regenerative therapies. (PubMed, Stem Cell Res Ther)
Circadian oscillators act as temporal gatekeepers of stem-cell function. Mapping the molecular interfaces between clock genes and developmental signaling pathways reveals new opportunities to refine regenerative therapies. Chronotherapeutic strategies, i.e. timing interventions to intrinsic circadian phases may enhance the efficacy, precision, and safety of stem-cell-based treatments.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
Akeega (abiraterone/niraparib)